Abstract
In a 6-week open-label study, ten newly admitted depressed patients were treated with tomoxetine, a selective inhibitor of noradrenaline reuptake. After 7 days of drug washout, patients were given an initial dose of 40 mg/day which was gradually increased to a maximum of 70 mg/day (median 50 mg/day). There was a statistically (P<0.001) and clinically significant improvement in the mean symptomatology of the patients measured on the Hamilton Depression Rating Scale. The drug had an early onset of action, a specific effect on mood and no sedative properties.
This is a preview of subscription content, log in via an institution to check access.
References
Bartko JJ, Carpenter WT (1976) On the methods and theory of reliability. J Nerv Ment Dis 163:307–317
Diagnostic and Statistical Manual of Mental Disorders (3rd ed) (1980) American Psychiatric Association, Washington, DC
Lilly Research Laboratories (1982) Clinical Investigation Manual LY139603. Eli Lilly and Company, Manual Identification Number: AS-6110
Wong DT, Threlkeld PG, Best KL, Bymaster FP (1982) A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 222:61–65
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chouinard, G., Annable, L. & Bradwejn, J. An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology 83, 126–128 (1984). https://doi.org/10.1007/BF00427436
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00427436